EndoTool SubQ

by MONARCH MEDICAL TECHNOLOGIES  · Based in United States →Making inpatient insulin management simple.
Endocrinology Hospital Medicine Pediatrics

Contact vendor
Regulatory Status Disclosed

Overview

EndoTool SubQ, developed by Monarch Medical Technologies (now part of Glooko as of September 23, 2025), is a software application designed to provide clinical decision support for subcutaneous insulin administration. It is used to manage blood glucose levels in both adult and pediatric patients (age 2 years and above and 12 kg or more). The tool utilizes proprietary model predictive control technology and feedback mathematics to model, predict, and adjust to each patient’s unique physiology and individual response to insulin, recommending the safest, most effective patient-specific dose.

EndoTool SubQ considers various factors that impact insulin response, including blood glucose level, height, weight, type of diabetes mellitus, age, sex, creatinine levels, steroids, carbohydrate intake, and ordered insulin. The software aims to reduce and eliminate correctional dosing, promote mealtime dosing, and prevent hypoglycemia by recommending supplemental carbohydrates if needed. As part of the broader EndoTool platform, it facilitates safe and easy transitions between intravenous and subcutaneous insulin therapies. The technology originated in 2003 with MD Scientific, which laid the groundwork for the EndoTool glucose management system.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Patient-specific insulin dosing recommendations
  • Model predictive control technology
  • Feedback mathematics for modeling and predicting insulin response
  • Adjusts to individual patient physiology
  • Considers various patient factors (BG, height, weight, diabetes type, age, sex, creatinine, steroids, carb intake, ordered insulin)
  • Reduces and eliminates correctional dosing
  • Promotes mealtime dosing
  • Recommends supplemental carbohydrates for hypoglycemia prevention
  • Supports adult and pediatric patients (age 2 and above)
  • Seamless transition between IV and SubQ insulin therapies (as part of EndoTool platform)

Use Cases

  • Inpatient subcutaneous insulin management
  • Hyperglycemia treatment in hospitalized patients
  • Hypoglycemia prevention in hospitalized patients
  • Transitioning patients from IV to subcutaneous insulin therapy
  • Standardizing insulin dosing protocols in hospitals
  • Improving glycemic control and patient safety in hospitals

What Physicians Need to Know

Evidence Base
EndoTool SubQ utilizes proprietary technology with an advanced machine-learning algorithm that models, predicts, and adjusts to each patient's unique physiology and individual response to insulin. It is FDA-cleared and considers over 11 patient-specific factors, including blood glucose, height, weight, type of diabetes, age, sex, creatinine levels, steroids, and carbohydrate intake. The system supports standardized glycemic management protocols and aligns with guidelines from organizations like the American Diabetes Association (ADA) and the Society of Critical Care Medicine (SCCM).
Clinical Validation Studies
Clinical studies have demonstrated significant improvements in glycemic control and patient safety. Temple Health reported a 71% reduction in hypoglycemia and an 85% drop in severe hypoglycemia after implementing EndoTool SubQ. The system also achieved zero severe hypoglycemia in renally impaired patients at Temple Health. Studies show an 80.6% relative risk reduction in hypoglycemia (180 mg/dL). It has been associated with reduced ICU and hospital lengths of stay, and a significant decrease in time to reach target blood glucose levels.
Alert Fatigue Management
EndoTool SubQ provides real-time clinical alerts (advisories) for urgent patient care needs, supporting prompt intervention. It proactively recommends supplemental carbohydrates to prevent impending hypoglycemic events. The system also determines the frequency of blood glucose monitoring based on glucose stability, which can help optimize alert frequency.
Override Rate Data
EndoTool Analytics provides records of dosage deviations from protocol and deleted blood glucose entries, allowing for detailed analysis by facility, unit, date range, and application. This functionality enables monitoring of when recommendations are not followed, providing insights into potential workflow issues or educational needs. The system is designed as an aid to clinical reasoning, implying that healthcare professionals can override recommendations based on their full clinical assessment.
Clinical Workflow Integration
EndoTool SubQ is designed for seamless integration with all major Electronic Medical Record (EMR) systems, with hundreds of successful integrations reported. It accepts clinical values, lab results, and point-of-care glucose readings directly from the EMR, streamlining workflow and promoting efficient mealtime dosing. The system simplifies complex insulin management and supports standardized processes within the hospital.
Decision Audit Trail
EndoTool Analytics provides robust data reporting capabilities, allowing healthcare teams to generate detailed reports with a single click. It tracks and analyzes trends in insulin regimen safety and effectiveness, including dosage deviations and deleted blood glucose entries. The system also provides 'Clinicians Late' reports to monitor timely blood glucose checks, and all drip run information and insulin doses are electronically saved for a comprehensive audit trail.
Physician Tip

Leverage EndoTool SubQ as a powerful decision *support* tool to individualize insulin dosing, moving beyond traditional sliding scales to achieve safer and more effective glycemic control. Pay close attention to the system's proactive alerts for hypoglycemia and utilize its analytics features to monitor adherence, identify workflow inefficiencies, and continuously refine your institution's glycemic management protocols, especially for high-risk patients like those with renal impairment or during transitions from IV to subcutaneous insulin.

EndoTool SubQ's proven ability to integrate seamlessly with major EMR systems is critical for maximizing its benefits. Ensure robust integration to enable automatic data exchange of patient demographics, lab values, and point-of-care glucose readings, which will streamline clinical workflows, reduce manual data entry errors, and provide a comprehensive, real-time view of patient glycemic status within your existing health IT infrastructure.

Details

Category Endocrinology & Metabolic AI, Pharmacology & Dosing AI
Pricing Contact vendor
DeploymentCloud-based (browser-based) and potentially thick client options.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

EndoTool SubQ received U.S. Food and Drug Administration (FDA) 510(k) clearance (K142918) on April 24, 2015. It is cleared for use by trained healthcare professionals to calculate and recommend an individual patient's next dose of insulin to be administered subcutaneously to manage blood glucose levels in adult and pediatric patients (age 2 and above and 12 kg or more).

Integrations
EHR Not specified
Specialties Endocrinology, Hospital Medicine, Pediatrics

What the Web Says

EndoTool SubQ is an FDA-cleared, patient-specific insulin dosing system designed to provide individualized insulin recommendations for subcutaneous insulin delivery in both adult and pediatric patients (age 2 and above). It utilizes advanced algorithms that consider various patient factors like blood glucose, height, weight, diabetes type, age, sex, creatinine levels, steroid use, and carbohydrate intake to recommend the safest and most effective dose. The system aims to improve glycemic control, reduce hypoglycemic and hyperglycemic events, and enhance clinician confidence in insulin dosing.

Overall: Positive

Strengths

  • Significant reduction in hypoglycemic events (both mild and severe).
  • Improved overall glycemic control and maintenance of target glucose ranges.
  • Enhanced clinician (especially nurse) confidence in insulin dosing.
  • Provides patient-specific, individualized insulin recommendations.
  • Streamlined workflow and reduced need for manual adjustments.
  • Ability to adjust recommendations rapidly in response to changes like missed meals or vomiting.

Limitations

  • Requires extensive training and institution-wide adoption.
  • Some initial studies showed no statistically significant difference in time to achieve target blood glucose or percentage of time within target range compared to paper protocols, although trends toward improved safety were noted.
  • Limited published research specifically on subcutaneous insulin guidance compared to intravenous versions of similar systems.
  • Some Reddit users mention it can be aggressive in bringing down blood glucose quickly, potentially overshooting.
  • Can be time-intensive for nurses due to frequent blood sugar checks, especially in the initial phases.

Based on reviews from: Monarch Medical Technologies, Temple Health, PubMed, Reddit (r/nursing), American Diabetes Association

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate EndoTool SubQ

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Medical Product Outsourcing
FDA Clears EndoTool SubQ from Monarch Medical
Monarch Medical Technologies received FDA 510(k) clearance for EndoTool SubQ, a solution that uses advanced proprietary technology and feedback mathematics to recommend subcutaneous insulin and carbohydrate doses for adult and pediatric patients (age 2 and above). The company states that this clearance comes at a critical time for hospitals as more patients require insulin during hospitalizations, and the platform aims to provide safe intravenous and subcutaneous insulin therapy.
unknown
Monarch Medical Technologies
EndoTool Subcutaneous Inpatient Insulin Dosing Solution Simplifies Provider Workflow While Improving Patient Safety
Monarch Medical Technologies announced FDA clearance for its enhanced software, EndoTool SubQ, designed to treat inpatient hyperglycemia using subcutaneous insulin. The solution aims to help hospitals move away from unsafe sliding-scale protocols and achieve rapid, safe glycemic control through its advanced machine-learning algorithm.
2021-11
Monarch Medical Technologies
Monarch Medical Technologies Receives FDA 510(k) Clearance for EndoTool SubQ
Monarch Medical Technologies received FDA 510(k) clearance for EndoTool SubQ, a solution that uses clinically-proven and patent-pending model predictive control technology to provide patient-specific subcutaneous insulin dose recommendations. The company emphasizes that this clearance is crucial as more patients require insulin during hospitalization, and the platform enhances the value of their EndoTool platform for safe and personalized treatment.
unknown
Monarch Medical Technologies
EndoTool SubQ: What You Should Know
This article describes EndoTool SubQ as a clinical decision support tool for subcutaneous insulin administration in all patient types, including pediatrics. It highlights the proprietary technology that models, predicts, and adjusts to each patient's unique physiology to recommend the safest and most effective patient-specific insulin doses.
2016-07
PMC - NIH
Evaluation of Several Electronic Glycemic Management Systems
This peer-reviewed article from 2018 mentions EndoTool Glucose Management System by Monarch Medical Technologies as a HIPAA-compliant clinical decision support software for personalized IV and SubQ insulin dosing. It notes that EndoTool SubQ calculates insulin dose recommendations based on multiple patient variables.
2018-01
Monarch Medical Technologies, A Glooko Company
EndoToolu00ae Patient-Specific Insulin Dosing System | Monarch Medical Technologies, A Glooko Company
This article highlights Temple Health's adoption of EndoTool SubQ in 2024, following their implementation of EndoTool IV, to provide individualized insulin recommendations. It emphasizes the system's unique algorithm that models each patient's clinical characteristics to provide optimal dosing and reduce severe hypoglycemia risk.
unknown
Monarch Medical Technologies
Monarch Medical Technologies Announces New Insulin-on-Board Adjustment for Subcutaneous Insulin Dosing
Monarch Medical Technologies announced FDA 510(k) clearance for an additional feature to EndoTool SubQ: an insulin-on-board (IOB) algorithm. This enhancement aims to further mitigate the risk of hypoglycemia by accounting for residual rapid-acting insulin activity.
2019-06
Hardian Health
Is post-market surveillance of AI devices working?
This article from June 2026 discusses the post-market surveillance of AI devices, including EndoTool SubQ, and notes that for most AI/ML product codes, there is minimal adverse event and recall information. It raises questions about the effectiveness of current post-market monitoring for AI in healthcare.
2026-06

Videos

Product demos, reviews, and walkthroughs for EndoTool SubQ.

Loading videos...

View all on YouTube

Frequently Asked Questions

EndoTool SubQ is a clinical decision support software that provides personalized insulin dosing recommendations for subcutaneous administration, considering various patient-specific factors like blood glucose, weight, age, and renal function. It utilizes proprietary technology to model and predict individual responses to insulin, aiming to optimize basal/bolus and corrective doses while reducing the risk of hypoglycemia and hyperglycemia.
Yes, EndoTool SubQ has received FDA 510(k) clearance, signifying its safety and effectiveness as a medical device. It is also designed to be HIPAA-compliant, and its dose recommendations can be configured to align with a hospital's internal guidelines and compliance requirements.
Alternatives to EndoTool SubQ include other commercial electronic glucose management systems like Glytec's Glucommanderu2122, GlucoStabilizeru00ae, and GlucoTabu00ae, as well as traditional paper-based insulin protocols or internally developed EMR-integrated tools. EndoTool SubQ differentiates itself by using a unique algorithm that models individual patient physiology and response to insulin, aiming for precise, patient-specific dosing and a reduction in severe hypoglycemia.
The pricing for EndoTool SubQ is not publicly disclosed as a fixed rate; instead, it varies based on the specific needs and healthcare setting of the implementing organization. Monarch Medical Technologies offers tailored pricing models, and institutions are encouraged to contact them directly for a detailed quote that fits their requirements and budget.
EndoTool SubQ serves as a clinical decision support *aid* and is not a substitute for a physician's clinical judgment. Final dose decisions must always consider the patient's full clinical status, and no medical decision should be made solely based on the software's recommendations. While it integrates with EMRs, some internally developed systems might offer more seamless integration without requiring users to exit and re-enter the EMR.
EndoTool SubQ is designed to integrate with most EHR systems, allowing for the seamless transfer of patient data, including blood glucose readings and laboratory values. It supports an efficient clinical workflow by promoting mealtime dosing and can accommodate various hospital protocols, with nurses typically entering clinical data and the system calculating the next dose.
EndoTool SubQ is indicated for use by trained healthcare professionals to manage blood glucose levels in both adult and pediatric patients with Diabetes Mellitus who are receiving subcutaneous insulin. It is cleared for use in pediatric patients aged 2 years and above, weighing 12 kg or more.

Related Tools

Virta Health
Virta Health
Endocrinology & Metabolic AI
Virta Health offers a virtual health program focused on reversing Type 2 diabetes, prediabetes, and obesity through a nutrition-first approach, continuous remote care, and personalized coaching.
PNOĒ
PNOĒ
Endocrinology & Metabolic AI
PNOĒ is a science-backed cardiometabolic analyzer that performs comprehensive breath-based assessments to measure 23 biomarkers, including VO₂ max, resting metabolic rate (RMR), fat burn efficiency, and biological age. It delivers a 360° snapshot of an individual's physiology by analyzing how oxygen flows through the lungs, heart, and cells. The insights generated are used to personalize nutrition, exercise, and longevity plans.
UpDoc Inc.
UpDoc Inc.
Clinical Decision Support & Reference
UpDoc is an FDA-cleared, enterprise-ready agentic clinical AI platform that integrates with EHRs to deploy AI agents for continuous, physician-governed care-related tasks, especially for chronic disease management.
GlucoSense
GlucoSense
Endocrinology & Metabolic AI
GlucoSense is an AI-powered CGM intelligence platform that provides personalized insights for individuals with diabetes and tools for population health management for healthcare providers and health plans. It integrates with various CGMs and wearables to offer real-time monitoring, AI-driven food logging, and simplified care team workflows.
Endobits
Bio-Conscious Technologies Inc.
Clinical Decision Support & Reference
Endobits is an automated decision-support platform for diabetes and metabolic health that collects real-time data from various devices, EMRs, and EHRs to triage patients and prioritize those needing intervention.
StackAI for Endocrinology Practices
StackAI
Documentation & Scribing
StackAI helps endocrinology practices deploy secure AI agents that automate patient support, summarize clinical context, and streamline document-driven workflows with enterprise governance and HIPAA-ready controls.

See all Endocrinology & Metabolic AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.